TY - JOUR
T1 - Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma
T2 - A retrospective study of the EBMT Lymphoma Working Party
AU - Tanase, A.
AU - Schmitz, N.
AU - Stein, H.
AU - Boumendil, A.
AU - Finel, H.
AU - Castagna, L.
AU - Blaise, D.
AU - Milpied, N.
AU - Sucak, G.
AU - Sureda, A.
AU - Thomson, K.
AU - Vandenberghe, E.
AU - Vitek, A.
AU - Dreger, P.
PY - 2015/3/9
Y1 - 2015/3/9
N2 - The objective of this registry study was to analyse the outcome of patients who underwent allogeneic or autologous haematopoietic stem cell transplantation (HSCT) for hepatosplenic T-cell lymphoma (HSTL), a rare and extremely aggressive peripheral T-cell lymphoma subtype. Patients were eligible if they had histologically verified HSTL and underwent HSCT between 2003 and 2011. Seventy-six patients were identified in the European Society for Bone and Marrow Transplantation database. Additional baseline and follow-up information could be obtained from the referring centres for 36 patients. Eleven of these were excluded following histopathology review, leaving 25 patients in the final study cohort (alloHSCT 18, autoHSCT 7). With a median follow-up of 36 months, 2 patients relapsed after alloHSCT, resulting in a 3-year progression-free survival of 48%. After autoHSCT, 5 patients relapsed and subsequently died. This study indicates that graft-versus-lymphoma activity conferred by alloHSCT can result in long-term survival for a substantial proportion of patients with HSTL.
AB - The objective of this registry study was to analyse the outcome of patients who underwent allogeneic or autologous haematopoietic stem cell transplantation (HSCT) for hepatosplenic T-cell lymphoma (HSTL), a rare and extremely aggressive peripheral T-cell lymphoma subtype. Patients were eligible if they had histologically verified HSTL and underwent HSCT between 2003 and 2011. Seventy-six patients were identified in the European Society for Bone and Marrow Transplantation database. Additional baseline and follow-up information could be obtained from the referring centres for 36 patients. Eleven of these were excluded following histopathology review, leaving 25 patients in the final study cohort (alloHSCT 18, autoHSCT 7). With a median follow-up of 36 months, 2 patients relapsed after alloHSCT, resulting in a 3-year progression-free survival of 48%. After autoHSCT, 5 patients relapsed and subsequently died. This study indicates that graft-versus-lymphoma activity conferred by alloHSCT can result in long-term survival for a substantial proportion of patients with HSTL.
UR - http://www.scopus.com/inward/record.url?scp=84924359717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924359717&partnerID=8YFLogxK
U2 - 10.1038/leu.2014.280
DO - 10.1038/leu.2014.280
M3 - Article
C2 - 25234166
AN - SCOPUS:84924359717
VL - 29
SP - 686
EP - 688
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 3
ER -